<DOC>
	<DOCNO>NCT02178657</DOCNO>
	<brief_summary>This trial aim test intra-arterial injection autologous bone marrow mononuclear cell acute ischemic stroke patient safe improve neurological outcome .</brief_summary>
	<brief_title>Intra-arterial Bone-marrow Mononuclear Cells Infusion Acute Ischemic Stroke</brief_title>
	<detailed_description>This study patient include diagnosed ischemic stroke sharply territory cerebral average artery fulfill criterion incorporation none exclusion sign informed assent . 76 patient randomize proportion 2:1:1 group control receive medical conventional treatment two group intervention receive unique intra-arterial infusion mononuclear autologous bone marrow stem cell ( one group dose 2 million BMSC kilogram weight another group dose 5 million BMSC kilogram weight ) . The three group patient follow 24 month . The randomization stratify depend NHSS score . This clinical trial voluntary substudy obtain information plasma biomarkers .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<criteria>Patients middle cerebral artery ( MCA ) acute ischemic stroke . Time stroke onset know treatment start day 1 7 onset . DWIMRI reliably show acute MCA ischemic lesion Magnetic resonance angiography ( MRA ) must confirm ipsilateral MCA permeability National Institute Health Stroke Scale score 620 inclusion Age 1880 year Written inform consent obtain Hemorrhagic stroke symptomatic hemorrhagic transformation Lacunar infarction Preocclusive stenosis total occlusion ipsilateral carotid artery Worsening ≥4 point National Institute Health Stroke Scale 24 hour previous inclusion , attributable edema hemorrhagic transformation suspicious malignant edema Decrease consciousness Glasgow Coma Scale &lt; 8 point Patients present previous malignant disease last 5 year , except basal cell carcinoma Contraindication MRI bone marrow harvest Previous diagnosis neurodegenerative disease Acute heart failure Hepatic renal dysfunction ( creatinine &gt; 2mg/dL ) Coagulopathy Severe comorbidity Pregnancy , childbearing potential ( unless certain pregnancy possible ) breast feed Modified Rankin Score ( mRS ) stroke ≥2 Participation clinical trial last 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Stroke</keyword>
	<keyword>Cell therapy</keyword>
	<keyword>Bone marrow</keyword>
</DOC>